April 17, 2022/eMedClub News/--On March 31, 2022, the clinical trial application of the innovative drug ARB202 developed by ARBELE, a biotechnology company in Hong Kong Science Park, was approved by the Australian TGA.
For the treatment of advanced gastrointestinal malignancies
.
This is the only CDH17xCD3 double anti-specific antibody approved for clinical use in the world
.
About ARB202
About ARB202 ARB202 is a First-in-Class bispecific antibody that targets gastrointestinal antigen CDH17 and T-cell CD3, developed based on Abella Pharma's unique and innovative CDH17 target
.
ARB202 has a unique affinity for anti-CDH17 and anti-CD3 differentiated structures.
While ensuring high specificity and high killing activity, it avoids the risk of systemic immune response caused by excessive activation of T cells, so it has good safety and pharmacokinetics.
Features and developability
.
Preclinical results showed that ARB202 effectively enhanced the interaction between T cells and CDH17-expressing gastrointestinal tumor cell lines, resulting in the activation of T cells and the release of IL-2, which effectively produced tumor cell killing
.
In vivo injection of low-dose ARB202 antibody can effectively inhibit tumor growth
.
At present, ARB202 has been officially approved by the Australian TGA to start a phase I clinical trial.
The indication is for advanced gastrointestinal malignant tumors.
Patient screening will continue in Hong Kong from this fall.
(FDA) clinical trials
.
About ARBELE
About ARBELE Founded in 2016, Abella Biopharma is focused on inventing and developing breakthrough and innovative immunotherapies, providing first-in-class cancer drugs and high-quality diagnostic screening platforms for early disease intervention
.
Abel is founded by senior drug R&D experts and executives who have worked for Johnson & Johnson, Roche, Sanofi and Bristol-Myers Squibb.
The team of scientists comes from Cambridge, Oxford, Harvard, and Hong Kong University.
Headquartered in Hong Kong, in Guangzhou, Seattle and Sydney have research and business units targeting high-mortality cancers such as stomach, pancreatic, colon, bile duct and liver cancers for which there are few current treatments
.
For more information on Arbelebio, please visit: https://
▲Hong Kong Science & Technology Park Campus
▲Hong Kong Science & Technology Park Campus
